GHR Antibody

What is a GHR antibody and what are its primary research applications?

GHR antibodies are immunological reagents designed to recognize and bind to specific epitopes on the growth hormone receptor, a membrane protein that mediates the effects of growth hormone in regulating body growth and metabolic processes . These antibodies serve as crucial tools in multiple research applications:

Western blotting applications typically detect GHR at approximately 120 kDa, though theoretical molecular weight is around 72 kDa due to extensive post-translational modifications including glycosylation . Immunohistochemistry and immunofluorescence allow visualization of GHR localization in tissues (particularly liver) and cultured cells (such as HepG2) . Flow cytometry confirms expression on cell surfaces, while immunoprecipitation isolates GHR and associated protein complexes for further analysis . Functional applications include neutralization studies to inhibit GH-induced signaling and development of receptor antagonists or agonists .

Most significantly, GHR antibodies enable investigation of receptor-mediated signaling pathways, particularly the JAK2/STAT5 cascade that controls gene expression patterns essential for growth and metabolism .

How do I choose between monoclonal and polyclonal GHR antibodies for my research?

The selection between monoclonal and polyclonal GHR antibodies should be based on experimental requirements:

Monoclonal antibodies:

• Provide consistent recognition of a single epitope with high specificity

• Demonstrate batch-to-batch consistency for longitudinal studies

• Excel in applications requiring discrimination between closely related epitopes

• Examples include CG-172 (specifically binds subdomain 1) , anti-GHRext-mAb (targets subdomain 2) , and B-10 (detects GHR from multiple species)

Polyclonal antibodies:

• Recognize multiple epitopes simultaneously, potentially providing stronger signals

• Better accommodate epitope changes that might occur during processing or fixation

• Often preferred for applications like IHC where antigen retrieval may alter epitopes

• Examples include AF1210 (used for neutralization studies) and 20713-1-AP (detects GHR in WB, IHC, and IF applications)

For signaling studies where conformational specificity is critical, monoclonal antibodies targeting specific subdomains (like anti-GHRext-mAb) provide clearer mechanistic insights . For general detection across multiple applications, polyclonal antibodies offer greater flexibility.

What validation strategies should be employed to confirm GHR antibody specificity?

Comprehensive validation of GHR antibodies requires multiple complementary approaches:

Species cross-reactivity testing:

• ELISA against GHBPs from different species (human, rat, sheep, bovine, porcine)

• Western blot analysis with tissue samples from multiple species

• Example: AN98 specifically reacts with porcine GHBP but not GHBPs from other species

Cellular validation:

• Flow cytometry analysis with cells expressing or lacking GHR

• Immunofluorescence microscopy comparing target and control cells

• Example: AN98 binds to CHO-pGHR but not to control cells

Functional verification:

• Competitive receptor binding assays to determine if antibodies share binding sites with GH

• Evaluation of effects on GH-induced signaling (JAK2/STAT5 phosphorylation)

• Example: Anti-GHRext-mAb inhibits GH-induced signaling but only partially inhibits GH binding

Control experiments:

• Western blot detection of expected molecular weight band (approximately 120 kDa for full-length GHR)

• Negative controls omitting primary antibody in IHC/IF studies

• Peptide competition assays to demonstrate binding specificity

Genetically modified systems (knockdown/knockout) provide the most definitive validation but require significant resources to implement.

How can GHR antibodies distinguish between GHR isoforms and variants?

GHR exists in multiple isoforms due to alternative splicing and genetic polymorphisms, which can be differentiated using carefully selected antibodies:

Exon 3 polymorphism detection:
The GHR exon 3 deletion polymorphism (d3/fl) affects GH responsiveness and can be identified through antibody-based "chemotyping" . This approach employs dual-ELISA using:

• Antibodies recognizing total GHBP (tGHBP) derived from all GHR forms

• Antibodies specific to exon 3-containing GHBP [E3(+)GHBP]

The ratio of E3(+)GHBP to tGHBP provides a definitive profile:

• fl/fl subjects: 96.6 ± 5.1% ratio

• d3/fl subjects: 57.1 ± 8.4% ratio

• d3/d3 subjects: negligible E3(+)GHBP detected

This chemotyping approach offers 100% concordance with PCR-based genotyping while eliminating the need for DNA samples .

Alternative promoter usage:
GHR is transcribed from at least two distinct promoters (GHR 1A and GHR 1B), with differential tissue expression patterns . Domain-specific antibodies coupled with tissue-specific expression analysis can identify these variants.

Soluble vs. membrane-bound forms:
Antibodies targeting different regions of GHR can discriminate between the membrane-bound receptor and its soluble form (GHBP) produced through proteolytic cleavage . Size-based separation methods combined with domain-specific antibodies facilitate this distinction.

How do epitope-specific GHR antibodies affect receptor signaling and proteolysis?

The GHR extracellular domain contains two subdomains with distinct functional roles, and antibodies targeting these regions produce dramatically different effects:

Subdomain 1-targeting antibodies:

• Often function as receptor agonists (e.g., CG-172)

• Can trigger JAK2/STAT5 signaling pathways similar to GH

• Useful for studying receptor activation mechanisms

Subdomain 2 and dimerization interface antibodies:

• Typically inhibit GH-induced signaling (e.g., anti-GHRext-mAb)

• Prevent GH-induced conformational changes and receptor dimerization

• Block JAK2/STAT5 phosphorylation without completely inhibiting GH binding

• May prevent GH-induced disulfide linkage between receptor molecules

Membrane-proximal region antibodies:

• Can affect GHR proteolysis at the metalloprotease cleavage site

• Some antibodies prevent phorbol ester-induced receptor proteolysis

• Impact GHBP production by modulating extracellular domain shedding

This domain-specific functionality allows researchers to selectively modulate receptor activity, providing valuable tools for dissecting GHR signaling mechanisms.

What are the methodological differences between GHR "genotyping" and "chemotyping"?

Traditional genotyping and antibody-based chemotyping offer complementary approaches to identifying GHR polymorphisms:

GHR Genotyping:

GHR Chemotyping:

Chemotyping offers practical advantages for clinical research where DNA samples may be difficult to obtain and provides additional information about circulating GHBP levels that may correlate with GH responsiveness .

How can anti-idiotypic antibodies function as GHR agonists?

Anti-idiotypic antibodies represent an innovative approach to creating GHR agonists:

An anti-idiotypic antibody is generated against the antigen-binding site of an antibody that recognizes growth hormone. These second-generation antibodies (Ab2β) can structurally mimic GH and activate GHR . For example, B-32 is a monoclonal anti-idiotypic antibody to GH that functions as an effective GHR agonist .

The development process involves:

• Immunizing rabbits with GH to generate anti-GH antibodies

• Purifying IgG fragments from immunized rabbits

• Using these anti-GH antibodies as antigens to immunize mice

• Screening for antibodies that mimic GH activity

Functional characterization demonstrates that these antibodies:

• Specifically bind to GHR expressed on target cells (verified by FACS and immunofluorescence)

• Activate JAK2/STAT5 signaling pathways similar to GH

• Produce phosphorylation kinetics comparable to GH in dose-response studies

These antibodies provide valuable research tools that complement recombinant GH, potentially offering different pharmacokinetic properties or binding characteristics.

What strategies can be employed to develop species-specific GHR antibodies?

Development of species-specific GHR antibodies (such as porcine-specific) requires systematic implementation of multiple techniques:

Immunization strategy:

• Use species-specific GHBP as the immunogen

• Immunize BALB/c mice with target protein emulsified in Freund's complete adjuvant

• Administer multiple booster injections at 14-day intervals

• Verify antibody production via ELISA before proceeding

Hybridoma technique:

• Fuse splenocytes from immunized mice with Sp2/0 myeloma cells

• Culture hybridomas in HAT medium

• Screen by ELISA to identify hybridomas producing antibodies against the target protein

Rigorous specificity testing:

• ELISA against GHBPs from multiple species (human, rat, sheep, bovine, porcine)

• Western blot confirmation of specificity

• Flow cytometry and immunofluorescence to verify binding to cells expressing the target receptor

• Competitive receptor-binding assays to determine binding characteristics

Functional validation:

• Test inhibition of species-specific GH binding to its receptor

• Evaluate effects on GH-induced signaling in relevant cell models

• Assess antagonist/agonist activity in appropriate functional assays

This systematic approach has yielded successful outcomes such as the AN98 antibody, which functions as a porcine GHR-specific antagonist with no cross-reactivity to GHRs from other species .

What are optimal storage and handling conditions for GHR antibodies?

Proper storage and handling significantly impact GHR antibody performance:

Storage conditions:

• Store at -20°C (typical recommendation)

• For long-term storage, maintain in buffer containing stabilizers (e.g., PBS with 0.02% sodium azide and 50% glycerol pH 7.3)

• Most antibody preparations remain stable for one year after shipment

• Small volume antibodies (20μl) often contain 0.1% BSA as an additional stabilizer

Handling recommendations:

• Avoid repeated freeze-thaw cycles

• For frequent use, store small working aliquots at 4°C (typically stable for 1-2 weeks)

• Centrifuge briefly before opening vials to collect all material at the bottom

• Use sterile techniques when handling to prevent microbial contamination

Application-specific dilutions:

• Western blotting: Typically 1:500-1:1000

• Immunohistochemistry: Generally 1:50-1:500

• Immunofluorescence: Usually 1:50-1:500

• Always optimize dilutions for each specific antibody and application

Proper handling ensures consistent results and extends the usable lifetime of these valuable research reagents.

What controls should be included when using GHR antibodies?

Rigorous experimental design requires appropriate controls when using GHR antibodies:

Negative controls:

• Omission control: Apply secondary antibody without primary antibody to detect non-specific binding

• Isotype control: Use concentration-matched irrelevant antibody of the same isotype

• Tissue/cell specificity control: Include GHR-negative tissues/cells

• Preabsorption control: Preincubate antibody with immunizing peptide before application

Positive controls:

• Known high-expressing tissues (liver, skeletal muscle)

• Recombinant GHR protein or transfected cell lines

• Previous validated samples with established staining patterns

Experimental controls:

• For functional studies: Include known GH-responsive cells (CHO-GHR, hepatocytes)

• For neutralization: Demonstrate dose-dependent inhibition of GH activity

• For signaling studies: Include positive control stimulation with GH

Validation controls:

• When possible, use multiple antibodies targeting different GHR epitopes

• Confirm specificity using genetic approaches (siRNA, CRISPR)

• For clinical samples, correlate results with patient data or established biomarkers

How can researchers troubleshoot common problems with GHR antibody applications?

Effective troubleshooting requires systematic identification and resolution of technical issues:

Western blotting challenges:

Immunostaining issues:

Functional assay complications:

Methodical troubleshooting approaches and careful documentation of optimization steps ensure consistent, reproducible results with GHR antibodies.

How can GHR antibodies facilitate studies of JAK/STAT signaling dynamics?

GHR antibodies provide unique capabilities for investigating JAK/STAT pathway activation mechanisms:

Temporal signaling dynamics:
GHR antibodies with agonist properties (like B-32 or CG-172) enable precise timing of receptor activation, allowing time-course studies of JAK2/STAT5 phosphorylation kinetics . Researchers can compare phosphorylation patterns initiated by GH versus antibody stimulation, providing insights into activation mechanisms and potential differences in signaling dynamics.

Domain-specific signaling requirements:
Antibodies targeting different GHR domains help dissect structural requirements for signaling:

• Subdomain 1-targeting antibodies that act as agonists demonstrate the sufficiency of this region for initiating signaling

• Dimerization interface antibodies that inhibit signaling highlight the necessity of proper receptor orientation

• Comparing signaling patterns between different antibody types reveals mechanistic details of receptor activation

Manipulation of signaling duration:
Antibodies can modulate signaling duration differently than native GH due to:

• Potentially different receptor internalization kinetics

• Altered receptor downregulation mechanisms

• Modified SOCS protein recruitment patterns

Species-specific signaling comparison:
Species-specific antibodies (e.g., AN98 for porcine GHR) facilitate comparative studies across species, revealing evolutionary conservation or divergence in signaling mechanisms .

This approach has revealed critical insights into GHR activation mechanisms that complement traditional biochemical and genetic approaches.

What challenges exist in using GHR antibodies for detecting soluble GHBP versus membrane-bound GHR?

Discriminating between membrane-bound GHR and its soluble form (GHBP) presents specific technical challenges:

Structural considerations:

• GHBP represents only the extracellular domain of GHR (lacking transmembrane and intracellular regions)

• Most antibodies recognize epitopes in the extracellular domain present in both forms

• Size differences (GHBP ~55-60 kDa vs. full-length GHR ~120 kDa) provide one discrimination method

Assay design challenges:

Methodological solutions:

• Dual-ELISA systems with capture antibodies against conserved regions and detection antibodies against form-specific epitopes

• Differential centrifugation to separate membrane-bound from soluble forms

• For exon 3 polymorphism detection, purified and biotinylated anti-E3(+)GHBP IgG improves sensitivity and specificity over conventional approaches

Biological significance:
Understanding the GHBP/GHR ratio has important implications:

• Acromegalic patients with the GHRd3 allele show lower circulating GH levels

• d3/d3 individuals demonstrate significantly lower serum tGHBP compared to fl/fl and d3/fl genotypes

• These variations may affect GH responsiveness and should be considered in both research and clinical contexts

How can conformationally-sensitive GHR antibodies advance understanding of receptor activation?

Conformationally-sensitive antibodies provide unique tools for studying GHR structural dynamics:

The GHR extracellular domain undergoes significant conformational changes upon ligand binding, which can be detected and manipulated using specialized antibodies . Anti-GHRext-mAb represents a prototype of such antibodies with several remarkable properties:

• Recognizes rabbit and human GHRs by immunoprecipitation, but less so after GH treatment

• Binds specifically to subdomain 2 but not subdomain 1

• Fails to recognize dimerization interface mutant GHRs that cannot signal

• Dramatically inhibits GH-induced JAK2/STAT5 phosphorylation

• Prevents GH-induced GHR disulfide linkage that reflects conformational changes

• Only partially inhibits GH binding, suggesting effects beyond simple binding inhibition

These properties allow researchers to:

• Track receptor conformational changes in real-time

• Trap receptors in specific conformational states

• Correlate conformational changes with downstream signaling events

• Identify critical structural elements required for receptor activation

Such antibodies have revealed that GHR activation requires specific orientation changes in subdomain 2 and proper alignment of the dimerization interface, advancing our understanding of molecular mechanisms underlying GH signal transduction .

What are emerging applications of GHR antibodies in clinical research?

GHR antibodies are increasingly valuable in translational and clinical research contexts:

Chemotyping as a clinical tool:
The chemotyping approach (using antibodies to determine GHR exon 3 polymorphism status) offers several advantages for clinical applications:

• Requires only serum samples rather than DNA

• Provides information about circulating GHBP levels

• Demonstrates 100% concordance with PCR-based genotyping

• May predict GH responsiveness in therapeutic settings

Biomarker development:
GHR antibodies enable quantification of soluble GHBP, which may serve as biomarkers for:

• GH sensitivity (lower GHBP in d3/d3 individuals)

• Metabolic status

• Prediction of response to GH therapy

• Growth disorders or acromegaly monitoring

Therapeutic antibody development:
Research antibodies provide frameworks for potential therapeutic applications:

• GHR antagonists for acromegaly or diabetic complications

• Domain-specific modulators to selectively affect certain GHR functions

• Species-specific approaches for veterinary applications

Multiparameter tissue analysis:
Advanced immunohistochemical applications using GHR antibodies may:

• Correlate GHR expression patterns with disease progression

• Identify patient subgroups most likely to respond to targeted therapies

• Map tissue microenvironments influencing GHR signaling

These emerging applications highlight the evolving role of GHR antibodies beyond basic research into clinically relevant contexts.

How might next-generation GHR antibodies further advance receptor biology?

Future developments in GHR antibody technology promise to expand research capabilities:

Single-domain antibodies (nanobodies):
These smaller antibody fragments could offer:

• Improved access to structurally hindered epitopes

• Enhanced tissue penetration for in vivo applications

• Greater stability under challenging experimental conditions

• Potential for intracellular delivery to target specific GHR domains

Bispecific antibodies:
Dual-targeting antibodies could:

• Simultaneously engage GHR and signaling partners

• Force specific conformational states

• Connect GHR to novel signaling pathways

• Create synthetic GHR-dependent cellular responses

Photoswitchable antibodies:
Light-controlled antibody binding could:

• Enable precise temporal control of receptor activation or inhibition

• Allow spatially restricted GHR modulation in complex tissues

• Facilitate reversible manipulation of receptor function

Integration with advanced imaging:
Next-generation antibodies compatible with super-resolution microscopy could:

• Reveal nanoscale GHR organization on cell membranes

• Track dynamic receptor clustering during activation

• Monitor interactions with signaling components in real-time

These developments would extend our understanding of GHR biology beyond current limitations and potentially unveil novel therapeutic approaches for GH-related disorders.